Angiotensin-converting Enzyme Inhibitors Have Adverse Effects in Anti-angiogenesis Therapy for Hepatocellular Carcinoma

• DOI: 10.21203/rs.3.rs-72739/v1
• Publication Date: 2020-09-10T11:35:49Z
• Authors: Su Zhang; Man Qing Cao; Zhen Yu Hou; Xiao Ying Gu; Yong Zi Chen; Lu Chen; Yi Luo; Li Wei Chen; Dong Ming Liu; Hong Yuan Zhou; Ke Yun Zhu; Zhi Wei Wang; Xi Hao Zhang; Xiao Lin Zhu; Yun Long Cui; Hui Kai Li; Hua Guo; Ti Zhang
• Keywords: Kidney cancer

Abstract Background: Currently, most clinicians prescribe angiotensin-converting enzyme inhibitors (ACEIs) to alleviate proteinuria caused by anti-angiogenic drugs (AADs) according diabetic nephropathy guidelines or expert recommendations. However, the efficacy ACEIs and potential cancer promoting effect are controversial. This study aimed at confirming whether beneficial in anti-angiogenesis therapy for hepatocellular carcinoma. Methods: In clinic, we observed impact of on AADs during treatment Next, established different tumor-bearing mouse models confirm that have any anti-cancer side effects AADs. Further, confirmed relevant mechanism vivo. Results: Our clinical data shown some carcinoma (HCC) patients experienced tumor progression administration hypertension We models, did not delay appearance but compromised anticancer is unrelated a change VEGF signaling pathway. showed combination flared production kidney-derived erythropoietin (EPO). turn, EPO compromises decreases antitumor activity. Conclusions: For AADs, no promote drug resistance. Kidney-derived mainly responsible induced